AIMEDBIO is developing therapeutic antibodies and antibody-drug conjugate (ADC) for the treatment of brain diseases and tumor.
AIMEDBIO focuses on unveiling the mechanism behind how cancer cells evade the immune system by studying macrophage, microglia and lymphocytes. We are also interested in modulating neuro-inflammation as therapeutic approaches targeting brain diseases
AIMEDBIO is currently using High Throughput/ Content Screening (HTS/HCS) Platform to robustly and efficiently identify novel therapeutics
AIMEDBIO uses Patient-derived Cell/Xenograft (PDC/PDX) to increase the success of translational research
BIG DATA ANALYSIS
Genome, transcriptome, epigenome, proteome and drug screening data are analyzed and applied to big data-driven drug discovery and development